Leadership
-
Mario Guti via Getty Images
Who is Dr. George Tidmarsh, the new director of CDER?
Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.
By Meagan Parrish and Michael Gibney • July 23, 2025 -
Mario Tama / Staff via Getty Images
J&J accelerates past Stelara’s fall with better-than-expected portfolio growth
Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.
By Michael Gibney • July 17, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Stock via Getty Images
Q&ANeed a DTC platform? Here’s how one company built its own.
Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.
By Amy Baxter • July 14, 2025 -
Stock via Getty Images
First 90 DaysAs its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Simone Steiner recently joined the French company to set the stage for launch.
By Amy Baxter • July 9, 2025 -
Stock via Getty Images
First 90 DaysA biopharma bolsters patient centricity and trial diversity goals through newly created role
Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.
By Alexandra Pecci • July 1, 2025 -
iStock via Getty Images
AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all
The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.
By Michael Gibney • July 1, 2025 -
Grandbrothers via Getty Images
Biopharma is on edge about NIH funding cuts and what the future holds for research
Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.
By Michael Gibney • June 26, 2025 -
Permission granted by Parabilis
Q&AHow a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.
By Michael Gibney • June 24, 2025 -
iStock via Getty Images
Biotech’s turning point: for every challenge, an opportunity in disguise
As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.
By Michael Gibney • June 20, 2025 -
Stock via Getty Images
How a patient group tackled research diversity for one disease and triggered change for pharma
A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.
By Meagan Parrish • June 17, 2025 -
Permission granted by Michael Moenning, Northlight Studio
ProfileA day in the life of GSK’s U.S. president
How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.
By Meagan Parrish • June 13, 2025 -
Getty Images via Getty Images
Can ‘reputational pull’ save biotech from pharma’s image problem?
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
By Michael Gibney • June 12, 2025 -
Win McNamee via Getty Images
Pharma’s wins and losses in the budget bill
Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.
By Amy Baxter • June 11, 2025 -
Permission granted by Novartis
ProfileThe former Wall Street analyst shaping Novartis’ big-picture strategy
Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.
By Michael Gibney • June 10, 2025 -
Stock via Getty Images
Biotech CEO confidence hits rock bottom amid policy shifts
A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.
By Meagan Parrish • June 4, 2025 -
Stock via Getty Images
AI expertise is pharma’s next big hiring need — here’s what companies should look for
The widespread hunt for candidates who are equally versed in tech and healthcare is making AI recruiting a challenge.
By Alexandra Pecci • May 29, 2025 -
iStock via Getty Images
With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon
Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.
By Michael Gibney • May 28, 2025 -
Chip Somodevilla via Getty Images
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change
Turnover of the top execs at pharma giants like J&J, AbbVie and Merck in the last few years illustrates the seismic industry shifts that often accompany leadership changes.
By Michael Gibney • May 22, 2025 -
Permission granted by Zealand Pharma
Q&A // First 90 DaysLilly’s former small molecule head makes the leap to a rising biotech in obesity
Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.
By Amy Baxter • May 21, 2025 -
Permission granted by Editas
Q&A // First 90 DaysA new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.
By Michael Gibney • May 15, 2025 -
Andrew Harnik via Getty Images
FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory
Who’s in, who’s out and which key positions are still left to be filled in an agency upended.
By Alexandra Pecci • May 13, 2025 -
iStock via Getty Images
With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?
Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.
By Michael Gibney • May 13, 2025 -
Michael M. Santiago via Getty Images
RFK Jr.’s autism fixation hearkens back to his stance on vaccines
The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.
By Amy Baxter • May 9, 2025 -
Jacob Bell/PharmaVoice
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.
By Michael Gibney • May 8, 2025 -
Kevin Dietsch via Getty Images
On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst
Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.
By Michael Gibney • May 6, 2025
